RxDoctor Payments Data

Thomas Li, MD

Internal Medicine · W Bloomfield, MINPI 1649224403

Payments from drug & device makers

$3,897in general payments, 2019–2025

Across 245 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$561
  • Lilly USA, LLC$400
  • Amgen$386
  • AbbVie$302
  • GSK$260
  • Pfizer$227
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,897 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$32,737
Medicare patients
52
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide28$35,437
RybelsusSemaglutide25$33,251
JanuviaSitagliptin Phosphate23$24,720
JardianceEmpagliflozin18$21,629
XareltoRivaroxaban24$21,601
OzempicSemaglutide23$21,181
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,215
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,180
Atorvastatin Calcium152$1,678
Losartan Potassium136$1,493
Pregabalin24$1,055
Rosuvastatin Calcium45$882
Amlodipine Besylate83$797
Albuterol Sulfate HfaAlbuterol Sulfate26$776
Metformin Hcl69$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$561$54,43248 claims
Lilly USA, LLCTrulicity$400$35,43728 claims
Boehringer IngelheimJardiance, Stiolto Respimat$214$26,80929 claims
MerckJanuvia$96$24,72023 claims
Johnson & JohnsonXarelto$184$21,60124 claims
GSKTrelegy Ellipta$260$8,21513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in W Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →